Resistance to infection and activation of the monocyto-macrophage system caused by Bacillus firmus and its fractions
Language English Country United States Media print
Document type Journal Article
PubMed
7959430
DOI
10.1007/bf02906811
Knihovny.cz E-resources
- MeSH
- Adjuvants, Immunologic isolation & purification pharmacology MeSH
- Macrophage Activation drug effects MeSH
- Bacillus subtilis immunology MeSH
- Bacillus immunology MeSH
- Bacterial Vaccines isolation & purification pharmacology MeSH
- Hepatomegaly etiology MeSH
- Microsomes, Liver drug effects metabolism MeSH
- Lipids isolation & purification pharmacology MeSH
- Listeriosis prevention & control MeSH
- Macrophages drug effects immunology MeSH
- Monocytes drug effects immunology MeSH
- Mice MeSH
- Splenomegaly etiology MeSH
- Cytochrome P-450 Enzyme System metabolism MeSH
- In Vitro Techniques MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Adjuvants, Immunologic MeSH
- Bacterial Vaccines MeSH
- Lipids MeSH
- Cytochrome P-450 Enzyme System MeSH
Crude lipids isolated from Bacillus firmus, but not from other bacilli, were previously found to induce significant resistance against Listeria monocytogenes infection in mice. In this study, formaldehyde- and heat-killed bacterins of eight Bacillus species and some cellular fractions of B. firmus were prepared and tested for further immunomodulatory activities. Crude lipids, their aqueous extract, LTA, Protodyne and Pex-residue preparations exhibited a strong anti-infection activity, whereas Pextract, P40 and all bacterins tested had no effect. Formaldehyde-killed bacterins, live bacteria and the P40 preparation of both B. firmus strains, as well as bacterins of both B. subtilis strains, induced pronounced splenomegaly in mice. Peptidoglycan and Pex-residue induced significant depression of cytochrome P-450 in mouse liver microsomes after application of 0.1 mg per mouse. Optimal conditions for obtaining a bacterial suspension exhibiting these immunomodulatory properties were elaborated.
See more in PubMed
Cancer Immunol Immunother. 1986;22(1):24-30 PubMed
Folia Microbiol (Praha). 1992;37(6):455-60 PubMed
Chemioterapia. 1985 Aug;4(4):310-2 PubMed
Asian Pac J Allergy Immunol. 1984 Jun;2(1):144-53 PubMed
Immunology. 1979 Dec;38(4):809-17 PubMed
J Clin Microbiol. 1987 Mar;25(3):540-5 PubMed
Proc Natl Acad Sci U S A. 1988 Oct;85(20):7452-6 PubMed
Eksp Onkol. 1985;7(5):18-20 PubMed
J Biol Chem. 1964 Jul;239:2370-8 PubMed
Chemioterapia. 1985 Dec;4(6):467-70 PubMed
Can J Biochem. 1968 Aug;46(8):899-904 PubMed
J Infect Dis. 1981 Jul;144(1):1-9 PubMed
Eksp Onkol. 1984;6(3):45-7 PubMed
Ann Immunol (Paris). 1982 Jul-Aug;133D(1):3-13 PubMed
Proc Soc Exp Biol Med. 1968 Feb;127(2):556-9 PubMed
Immunology. 1982 Jul;46(3):481-6 PubMed
Immunol Lett. 1981 Apr;3(1):39-43 PubMed
Acta Pathol Microbiol Scand C. 1981 Dec;89(6):373-8 PubMed
Boll Ist Sieroter Milan. 1987;66(5):391-4 PubMed
Neoplasma. 1984;31(1):65-74 PubMed
Mikrobiol Zh. 1986 Jan-Feb;48(1):77-81 PubMed
Immunology. 1986 Aug;58(4):577-81 PubMed
Immunomodulatory properties of subcellular fractions of a G+ bacterium, Bacillus firmus
Immunomodulatory effects of Bacillus firmus on mouse peritoneal cells in vitro
Immunostimulatory effect of Bacillus firmus on mouse lymphocytes
Immunomodulatory effects of Bacillus firmus
Polyclonal activation of human lymphocytes by Bacillus firmus and its constituents
